Search results
Results From The WOW.Com Content Network
In about a third of cases, [7] VZV reactivates in later life, producing a disease known as shingles or herpes zoster. The individual lifetime risk of developing herpes zoster is thought to be between 20% and 30%, or approximately 1 in 4 people. However, for people aged 85 and over, this risk increases to 1 in 2. [8]
Shingles, also known as herpes zoster or zona, [6] is a viral disease characterized by a painful skin rash with blisters in a localized area. [2] [7] Typically the rash occurs in a single, wide mark either on the left or right side of the body or face. [1]
The incidence of herpes zoster, and also developing postherpetic neuralgia, both increase with age. [17] The frequency and severity of postherpetic neuralgia increase with advancing age, occurring in 20% of people age 60–65 years old who have had herpes zoster, and in more than 30% of people over 80 years old. [20]
What it looks like: Also known as herpes zoster, shingles is a blistering rash. It often appears in a stripe or in the top quadrant of the head, but only on one side of the body.
Chickenpox, also known as varicella (/ ˌ v ɛ r ə ˈ s ɛ l ə / VER-ə-SEL-ə), is a highly contagious disease caused by varicella zoster virus (VZV), a member of the herpesvirus family. [3] [7] [5] The disease results in a characteristic skin rash that forms small, itchy blisters, which eventually scab over. [1] It usually starts on the ...
Nine herpesvirus types are known to primarily infect humans, [7] at least five of which are extremely widespread among most human populations, and which cause common diseases: herpes simplex 1 and 2 (HSV-1 and HSV-2, also known as HHV-1 and HHV-2; both of which can cause orolabial and genital herpes), varicella zoster (VZV or HHV-3; the cause ...
A zoster vaccine is a vaccine that reduces the incidence of herpes zoster (shingles), a disease caused by reactivation of the varicella zoster virus, which is also responsible for chickenpox. [8] Shingles provokes a painful rash with blisters, and can be followed by chronic pain ( postherpetic neuralgia ), as well as other complications.
The usage expanded to include topical treatment of herpes simplex, [102] zoster, and varicella. [103] Some trials combined different antivirals with differing results. [ 97 ] The introduction of 9-β-D-arabinofuranosyladenine, (ara-A or vidarabine), considerably less toxic than ara-C, in the mid-1970s, heralded the way for the beginning of ...